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The purpose of this study was to investigate molecular changes associated with glioma tissues by Raman microspectroscopy in order to
develop its use in clinical practice. Spectroscopic markers obtained from C6 glioma tissues were compared to conventional histological and
histochemical techniques. Cholesterol and phospholipid contents were highest in corpus callosum and decreased gradually towards the cortex
surface as well as in the tumor. Two different necrotic areas have been identified: a fully necrotic zone characterized by the presence of plasma
proteins and a peri-necrotic area with a high lipid content. This result was confirmed by Nile Red staining. Additionally, one structure was detected
in the periphery of the tumor. Invisible with histopathological hematoxylin and eosin staining, it was revealed by immunohistochemical Ki-67 and
MT1-MMP staining used to visualize the proliferative and invasive activities of glioma, respectively. Hierarchical cluster analysis on the only
cluster averaged spectra showed a clear distinction between normal, tumoral, necrotic and edematous tissues. Raman microspectroscopy can
discriminate between healthy and tumoral brain tissue and yield spectroscopic markers associated with the proliferative and invasive properties of
glioblastoma. Development of in vivo Raman spectroscopy could thus accurately define tumor margins, identify tumor remnants, and help in the
development of novel therapies for glioblastoma.
© 2007 Elsevier B.V. All rights reserved.Keywords: Raman imaging; Glioma; Invasion; Necrosis; Brain structure; Edema1. Introduction
In spite of clinical and technological advances in the under-
standing and treatment of glioma, the survival of patients has not
notably improved. Indeed, malignant glioma produces profound
and progressive disability leading to death inmost cases.Moreover,
these tumors remain mostly refractory to standard therapies (such
as surgery, radiotherapy and conventional chemotherapy), and new
therapeutic approaches are clearly needed [1].
Surgery remains the most commonly used therapeutic
approach. However, complete resection of the tumor is only
carried out in less than 20% of patients, highlighting the difficulty
in clearly defining tumoral limits during surgery due to its invasive⁎ Corresponding author. Tel.: +33 3 2691 8376; fax: +33 3 2691 3550.
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doi:10.1016/j.bbamem.2007.06.032nature [2–5]. In order to improve drug treatments and to facilitate
their clinical evaluation, it thus appears capital to find newmarkers
defining tumoral margins through biology or medical imaging. As
such, the development of a methodology enabling grading and
prognosis of glioma would be of clinical benefit.
Raman spectroscopy is a vibrational spectroscopic technique
with a high molecular specificity that can be used in medical
diagnostics [6]. This technique has been successfully applied in the
diagnosis of cancers such as those of the skin, breast, oesophagus,
colorectum, and urogenital tract [7]. Raman spectra, resulting from
inelastic scattering of light by the molecules present in a sample,
provide information about the molecular composition, molecular
structures, and molecular interactions in a tissue. They also reflect
changes in the molecular composition and structures associated
with disease. The success of Raman spectroscopy as a biomedical
tool lies in its potential for in vivo applications and its ability to
guide real-time therapeutic interventions.
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and functional structures of rat brain, and were the first to publish
spectra of different brain tumors [8,9]. Recently, several Raman
studies have been published that constitute a basis for subsequent
studies to develop classification models for diagnosis of human
brain tumor [10,11]. Moreover, Krafft et al. suggested the use
Raman spectroscopy as a diagnostic tool to distinguish normal from
tumoral tissue, and to determine the tumor type and grade [12].
Therefore, the purpose of our study was to use Raman spectro-
scopic imaging to discriminate between healthy and tumoral tissue
and to identify spectroscopic markers associated with tumor pro-
gression and invasion, as well as tumor growth and necrosis. This
study will help in the future development of in vivo Raman
spectroscopy to accurately define tumor margins, to identify tumor
remnants and to develop novel therapies for glioblastoma.
2. Materials and methods
2.1. Animal procedures
All animal procedures adhered to the “Principles of laboratory animal care”
(NIH publication #85-23, revised 1985). Male Wistar rats weighing 409±85 g
(mean±SD) were purchased from Harland (Paris, France). All animals were
kept individually in standard animal facilities (20±2 °C; 65±15% relative
humidity) and maintained under a 12:12 h light/dark cycle. They were given free
access to food (Harlan Tecklad, France) and water throughout the study.
The C6 glioma tumor line used in this study and the cell inoculation
procedure have been described elsewhere [13]. Briefly, rats were anesthetized
with isoflurane and placed into a stereotactic head holder (Phymep, France).
A small burr hole was drilled into the right side of the skull (anterior 1 mm;
lateral 3 mm; lateral depth 4 mm, according to the bregma). Then, a tumor cell
suspension (5.106 cells in 10 μl DMEM/NUT.MIX.F-12) was injected with a
syringe over 2 min. After tumor cell implantation, the hole was closed with bone
wax, and rats allowed to recover from anaesthesia.
2.2. Sample handling and preparation
Twenty days after tumor cell injection, control and tumor-bearing rats were
sacrificed. After brain excision, tissue samples were snap-frozen by immersion
in methyl-butane cooled down in liquid nitrogen and stored at −80 °C. For
Raman spectroscopic studies, 15-μm-thick brain sections were made with a
cryotome and placed onto calcium fluoride slides (CaF2). After Raman
measurements, all tissues were hematoxylin and eosin (H&E) stained to provide
direct comparison of the Raman mapping results to histopathology.
2.3. Ki-67 immunostaining
Tissues were fixed in 10% buffered formalin, routinely processed, and
embedded in paraffin. Immunohistochemical studies were performed on 3- to 6-
μm-thick sections. Sections were deparaffinized and subjected to heat-induced
epitope retrieval by steaming for 10min. Slideswere then incubated at 4°Covernight
with an antibody recognizing the nuclear antigen Ki-67 (Rabbit Monoclonal, 1:200;
Labvision Corporation, UK). Antibodies were detected using universal immuno-
peroxidase polymer for rat tissue sections anti-mouse and anti-rabbit primary
antibodies (N-Histofine Simple Stain Rat MAX PO, Nichirei Corporation, Japan).
Amygdale tissue was used as a positive control. Healthy brain tissue served as the
negative control. Sections were counterstained with hematoxylin.
2.4. MT1-MMP Immunostaining
Tumor sections (3–4 μm thick) were cut from formalin-fixed, paraffin
embedded brain tissue. They were hydrated through graded alcohols and
incubated in H2O2 (3% 10 min). They were then subjected to heat-induced
epitope retrieval in citrate buffer (pH 6) by steaming for 10 min (Dako, Glostrup,Denmark). Sections were treated with the primary mouse anti-human-MT1-
MMP monoclonal antibody, whose expression correlates with tumor invasion,
(113-5B7, 1:100, Fuji Chemical Industries, Japan) for 24 h in the cold. They
were then treated for 30 min at room temperature with universal immuno-
peroxidase polymer for rat tissue sections anti-mouse and anti-rabbit primary
antibodies (N-Histofine Simple Stain Rat MAX PO, Nichirei Corporation,
Japan). Healthy brain tissue served as the negative control. Sections were
counterstained with hematoxylin.
2.5. Nile red staining
Stock solutions of Nile red (500μg/ml) were prepared by dissolvingNile blue
A chloride (Cl 51180; Sigma-Aldrich, Saint Quentin Fallavier, France) in acetone
and stored chilled and protected from light. Fresh solutions of Nile redweremade
by adding 2–10 μl of the stock solution to 1ml of 75% glycerol followed by brisk
vortexing. The glycerol-dye solution was then briefly degassed by vacuum.
To stain frozen sections (6–10 μm thick), a drop of the glycerol staining solution
was added to each section and the preparation covered with a glass coverslip. After
1 h, sections were examined by fluorescence microscopy at two spectral settings:
yellow-gold fluorescence and red fluorescence. As such, neutral lipids were seen as
yellow-gold fluorescent structures; whereas the red fluorescent structures, which are
yellow-gold fluorescence negative, were mainly composed of phospholipids, other
amphipathic lipids, and strongly hydrophobic proteins of cell membranes.
2.6. Reference Raman spectra
Raman reference spectra were obtained from specific lipids dissolved in
chloroform and placed onto a CaF2 slide. The following chemicals were
purchased from Sigma-Aldrich (Saint Quentin Fallavier, France) and used
without further purification: Cholesterol (99%), phosphatidylcholine (1,2-
diacyl-sn-glycero-3-phosphocholine, 99%, from egg yolk), phosphatidyletha-
nolamine (1,2-dihexadecanoyl-sn-glycero-3phosphoethanolamine, 99%), sphin-
gomyelin (N-acyl-D-sphingosine-1-phosphocholine, 99%, from bovine brain),
galactocerebroside (ceramide β-D-galactoside, 99%, from bovine brain).
2.7. Raman spectroscopy
Raman spectra of tissue sections were recorded with a near infrared confocal
Raman microspectrometer (Labram, Horiba Jobin Yvon S.A.S., France). The
setup consisted of a microscope (Olympus, HB40, France) coupled to the
Labram spectrometer. The microscope was equipped with a xy-motorized
(Marzhauser, Germany), computer-controlled sample stage, which enabled
automatic scanning of the sample with a resolution of 1 μm. The excitation
source (785 nm) was provided by a titanium-sapphire laser (Model 3900S,
Spectra-Physics, France) pumped with an Argon ion laser. The laser power on
the sample was around 160 mW. This laser light was focused on the sample with
a 100× optimized objective (Olympus, France). This objective collected light
that was scattered by the sample, which was then analyzed by the spectrometer
equipped with a Pelletier-cooled charge-coupled device detector. The Raman
signal was collected using 5 s of signal collection time per Raman pixel in the
600- to 1800-cm−1 spectral region with a spectral resolution of 4 cm−1. For our
measurements, the objective was set on autofocus. This system allowed focusing
the laser light on each point of the tissue section. Unstained cryosections were
placed on the microscope. A screen image recorder camera attached to the
microscope enabled the acquisition of the white light multi-image of the area
under investigation. Raman maps were recorded by defining a scanning xy-step
size of 50 μm as controlled by the LabSpec software (Horiba Jobin Yvon S.A.S.
France). The 100× objective collected light on a 3- to 4-μm spot. The xy-step
size was chosen based on previous studies (unpublished results) that showed that
higher resolution Raman maps with a 15-μm xy-step size did not bring any
additional information than those measured with a 50-μm step size.
2.8. Spectroscopic data analysis
Raman data were analyzed with custom software developed in MatLab
(MathWorks, Inc., Matick, USA). After acquisition, spectra were first calibrated
using Raman calibration standards [14]. The spectrum of the halogen lamp was
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Raman setup. Spectral pre-treatment also involved subtraction of the interfering
background Raman signal originating from the optical elements in the laser light
delivery pathway, the CaF2 slide, and the interfering glue biopolymer used
during freezing.
Raman maps were constructed from the spectral data using multivariate
statistical techniques. Data were first scaled using a Standard Normal Variate
(SNV) transformation [15]. As such, every spectrum was mean centered (so that
the average of the spectral intensities in all wavenumber channels was set to
zero) and scaled to have a standard deviation of one. Principal component
analysis (PCA) was used to identify the independent sources of variation in all
spectra and to reduce the number of variables describing the data set. An
unsupervised classification method (k-means cluster analysis) was then used to
find groups of spectra that shared similar spectral characteristics. Thirty PCA
scores, accounting for 99.9% of the captured variance, served as input for the
unsupervised classification methods. The cluster-membership information was
then plotted as a pseudo-color map by assigning a color to each different cluster.
Pseudo-color Raman maps were then compared with histopathology results
using HE-stained tissue sections. Positive difference spectra between clusters
describing normal and tumor tissue structures were computed to determine the
inter-cluster variance. These cluster average spectra were then used as input for
hierarchical cluster analysis using Ward's clustering algorithm and the square
Euclidian distance measure. This method was used to identify the discriminant
characteristics between normal and tumor brain tissues.
3. Results
Raman Maps were obtained from unstained frozen sections of
normal and glioma tumor tissues. Pseudo-color maps were
constructed after multivariate statistical analysis (PCA, clustering
analysis) and compared to histopathology results in order to
correlate each pseudo-color with its anatomical counterpart. The
aim of thismethodwas to identify common and specific structures
in normal and tumor brain tissues, and to spatially visualize these
structures in the pseudo-color maps. Twelve clusters describing
both healthy and cancer features were extracted, and pseudo
Raman maps were constructed with the same color scale (white
color representing areas where no tissue was present). In some
samples, Raman maps and microscopic images of the H&E
stained section were found to correlate well. In other samples,
information complimentary to histopathology was obtained from
cluster analysis leading to a better identification of the molecular
changes associated with brain tissue alteration.
3.1. Healthy brain tissue
An example of the results of a Raman mapping experiment on
normal brain tissue is shown in Fig. 1E. In this pseudo-color map,
seven or twelve clusters were sufficient to describe all brain
features. Comparison of this pseudo-color map with the
microscopic image of the stained tissue section (Fig. 1A) enabled
identification of the anatomical structures of the rat brain.As such,
the area associated to the spatial distribution of cluster 9 correlates
with white matter tissue from the corpus callosum (CC). Tissue
surroundingCCwas encoded by cluster 12. Other clusters (1, 3, 8,
and 10) described the cortex (Gray matter). Clusters 2 and 7
described blood and could be associated to the vascularisation.
Cluster averaged Raman spectra are shown in the same figure
(Fig. 1). All extracted models exhibited bands of proteins and
lipids as the main constituents of brain tissue. The band at
718 cm−1 can be assigned to phospholipids such as phosphati-dylethanolamine (Fig. 2f) and/or phosphatidylcholine (Fig. 2h).
The band at 1002 cm−1 was assigned to the aromatic amino-acid
phenylalanine. Bands at 1062, 1128, and 1296 cm−1 correspond
to aliphatic side chains, the band near 926 cm−1 to the C\C bond
of the peptidic backbone, and bands at 1266 and 1658 cm−1 to the
amide III and amide I vibrations of the peptidic backbone,
respectively. All major protein bands at 1266, 1296, 1436 and
1658 cm−1 strongly overlap with lipid bands. All spectra
corresponding to normal brain structures were characterized by
a specific variability in those peak positions and intensities.
Positive difference spectra between clusters describing normal
structures were computed to determine the changes between
clusters averaged spectra (Fig. 2). These spectra give a good
estimation of molecular species present in a relatively high
amount in one spectrum as compared to the other. The difference
spectrum between cluster 9 associated to CC and cluster 12
corresponding to adjacent tissue is presented in Fig. 2a. This
spectrum shows bands at 700 cm−1, 1062 cm−1 (C\O stretching
and C\O\C symmetric stretching), 1128 cm−1 (C\C stretch-
ing), 1266 cm−1 (in plane CH2 deformation), 1296 cm
−1 (CH2
and wagging), 1436 cm−1 (CH2 bending), and 1670 cm
−1 (C_C
stretching). This difference spectrum contains a combination of
bands that are characteristic of cholesterol (Fig. 2e) and
phospholipids, especially phosphatidylethanolamine and galac-
tocerebroside (Fig. 2f and g, respectively).
Comparison between pseudo-color map and the histopathol-
ogy image (Fig. 1E and A) shows that the Raman image provides
more information than standard histopathology staining in the
cortex. As such, four layers were identified from the cortex,
whereas H&E staining did not allow to discriminate these layers.
Difference spectra between these cortex layers (Fig. 2b, c, and d)
obtained by subtracting models spectra of successive layers
(clusters 12-10, 10-1, and 1-3 respectively) were calculated.
Comparison of these difference spectra showed that the band
located at 700 cm−1, characteristic of cholesterol, decreased from
spectrum b to spectrum d (Fig. 2) suggesting that cholesterol
content decreased gradually from CC to cortex, and even
disappeared in the upper cortex layers. On the other hand,
phospholipids bands, more pronounced in trace b, tended to
decrease in traces c and d.
3.2. Brain tumor tissue
Molecular changes associated with malignant rat brain tumor
were investigated. Fig. 1F toH showRamanmaps of glioma brain
tissues. These pseudo-color maps share some common structures
with normal tissue such asCC (cluster 9), and cortex (clusters 1, 3,
10, and 12). Since the molecular composition of tissue is altered
by tumor invasion, other clusters were assigned to tumor tissue
(clusters 4, 5, 6, 8, and 11). All clusters associated with tumor (see
Fig. 1) showed a decrease in the intensity of the lipids bands at
700, 1062, 1128, and 1296 cm−1 corresponding to cholesterol and
phospholipids. In contrast, other bands were more pronounced in
the tumor model such as bands at 782 and 826 cm−1 attributed to
DNA and/or RNA. As shown in Fig. 1, comparison of pseudo-
color maps (F, G, and H) with their respective histopathological
images (B, C, and D) revealed that clusters 5 and 6 (blue and red
Fig. 1. Photomicrographs (H&E staining) of healthy (A) and glioma (B–D) brain tissue sections. Pseudocolor Raman maps E–H are based on 12-means cluster analysis on sections A–D, respectively. As per contra,
representative cluster-averaged Raman spectra collected from healthy and glioma brain tissue sections. Spectra are shown with the same color than in the pseudocolor maps E–H.
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Fig. 2. Positive difference between cluster averaged spectra associated to healthy tissue. (a) Cluster 9 minus cluster 12; (b) Cluster 12 minus cluster 10; (c) Cluster 10
minus cluster 1; (d) Cluster 1 minus cluster 3. Raman spectra of pure compounds. (e) Cholesterol; (f) Phosphatidylethanolamine ; (g) Galactocerebroside;
(h) Phosphatidylcholine.
2609N. Amharref et al. / Biochimica et Biophysica Acta 1768 (2007) 2605–2615color, respectively) correspond to the tumor area, whereas cluster
4 (yellow color) encodes the surrounding tumor. Moreover, a
particular region described by cluster 11 (Fig. 1H) was identified.
To findmolecular species that are only present in normal but not
in tumor tissue and vice versa, two positive difference spectra
between normal and tumor models were calculated. Fig. 3a
displays the difference spectrum between cluster 1 (describing a
cortex layer) and cluster 5 (associated to tumor). This spectrum
showed a high lipid content, in particular cholesterol (band at
700 cm−1) and phosphatidylcholine and/or phosphatidylethanol-
amine (bands at 718, 1128, 1296, and 1734 cm−1). Other changes
involve the presence of bands at 782, 826, and 1104 cm−1
attributed toDNA conformation. On the other hand, analysis of the
difference spectrum between cluster 5 and cluster 1 (Fig. 3b),
similar to that of blood (Fig. 3f), showed a major protein content.
To identify themolecular changes between tumor (cluster 5) and its
surrounding area, a difference spectrum (cluster 4 minus cluster 5)was calculated. The resulting spectrum (Fig. 3c) was comparable
to that of blood (Fig. 3f). To determine the particular structure
described by cluster 11, a difference spectrum between cluster 11
and tumor (cluster 5) was calculated (see Fig. 3d). This difference
spectrum, as it possesses bands similar to those of plasma (Fig. 3e),
shows that cluster 11 could be assigned to edema, a result in
agreement with the anatomopathologist's opinion. Incidentally,
the H&E examination of the section showed interstitial spaces
characteristic of extracellular fluid volume enlargement (Fig. 4D).
To better understand the specific spectral changes associated
with healthy and diseased states of tissue, comparisons between
pseudo-color Raman maps and immunostaining were performed.
Immunohistochemistry pointed out that the proliferation activity
of tumors can be assessed bymeans of Ki-67 staining, a technique
commonly used in clinical pathology and neuropathology
diagnostics. Fig. 4A shows Ki-67 staining of the area defined
by a black frame in Fig. 1B. It reveals an important nuclear
Fig. 3. Positive difference between cluster averaged spectra associated to tumor tissue. (a) Cluster 1 minus cluster 5; (b) cluster 5 minus cluster 1; (c) cluster 4 minus cluster 5; (d) cluster 11 minus cluster 5; Raman spectra
of (e) plasma and (f) blood. (g) Cluster 2 minus cluster 7; (h) cluster 7 minus cluster 8; (i) cluster 8 minus cluster 2; (j) cluster 8 minus cluster 7. (k) Raman spectrum of Oleic acid.
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Fig. 4. Immunohistochemical staining (A) and (B) obtained on area marked with a black frame in Fig. 1B. (A) is a Ki-67 immunostaining demonstrating an increased
staining in the area surrounding the tumor, (B) is a MT1-MMP immunostaining showing an increased expression of this metalloproteinase in tumor borders.
Immunohistochemical staining (C) and (D) obtained on area marked with a black frame in Fig. 1C and D, respectively. (C) and (C1) are Ki67 immunostaining pointing
out the pseudopalisading area. Fluorescence confocal microscopic images (C2), (C3) of the perinecrotic zone, and (C4) of the central necrotic zone, after Nile red
staining. (D) H&E staining of edema zone.
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activity of the cells from the area surrounding the tumor
associated to cluster 4. To correlate this proliferative activity
with the tumor invasion, MT1-MMP immunostaining was
performed. Fig. 4B shows MT1-MMP staining on the same
area, pointing out an over-expression of MT1-MMP by the
peripheric tumor cells associated to the aggressive invasiveness of
these tumor cells. The correlation between immunohistochemis-
try staining results and spectroscopic data shows the potential of
Raman spectroscopy to identify spectroscopic markers associated
with proliferative and invasive properties of glioblastoma. Ki-67
immunostaining of the tumor section (corresponding to the area
marked by the black frame in Fig. 1C), as displayed in Fig. 4C,
revealed two important areas: (i) a central necrotic areawith a total
absence of proliferation associated with pycnotic cells, blood
components and cellular debris and, (ii) pseudopalisading cells
with lower Ki-67 proliferation indices associated with the
perinecrotic area (Fig. 4C1). Necrotic area and perinecrotic
zones were associated to clusters 2, 7, and 8 (see Fig. 1G).
Difference spectra between cluster 2 and cluster 7 (Fig. 3g) as
well as between cluster 7 and cluster 8 (Fig. 3h) were similar to
that of plasma (Fig. 3e), suggesting the presence of blood in the
center of the necrotic area and in the region associated with
proliferative activity. On the other hand, difference spectra
between cluster 8 and cluster 2 (Fig. 3i) and between cluster8 and cluster 7 (Fig. 3j) were similar to that of oleic acid (Fig. 3k)
with an additional band at 700 cm−1 associated with cholesterol.
To identify the nature and the distribution of these lipids in
tissue, Nile red staining was used. This technique revealed in the
perinecrotic area the presence of phospholipids and neutral lipids
(red fluorescence structures and yellow-gold labelling respec-
tively; Fig. 4C2) associated with the presence of lipid droplets
with a diameter of about 0.5 to 1 μm (visible in Fig. 4C3 with
high magnification). Fig. 4C4, however, illustrates an absence of
neutral lipids in the fully necrotic zone and the poor staining of
the necrotic and pycnotic cells characterized by an altered
cytoplasm and condensed nuclear. Nile red staining results were
in agreement with those obtained by Raman spectroscopy
showing a more important lipid distribution for cluster 8 than for
clusters 2 and 7. In fact, the center of the necrosis (full necrosis)
seems to correspond to cluster 2, whereas the peri-necrotic and
necrotic zones (pseudopalisading and pycnotic cells, respec-
tively) seem to be encoded by cluster 7 and 8.
To distinguish between normal, tumor, and necrotic brain
structures, cluster averaged spectra obtained from pseudo-color
maps were input in the hierarchical cluster analysis. The result, as
shown on the dendrogram in Fig. 5, showed a clear distinction
between all normal and tumor brain structures. Indeed, in the
cluster-averaged spectra of normal brain structures, two sub-
clusters associated with white matter (clusters 9 and 12
Fig. 5. Dendrogram obtained from hierarchical cluster analysis on spectral
cluster averages associated to different tissue types. Heterogeneity represents the
discriminating distance given by arbitrary units (au).
2612 N. Amharref et al. / Biochimica et Biophysica Acta 1768 (2007) 2605–2615corresponding to higher cholesterol content) and grey matter
(clusters 1, 3, and 10 with a lower cholesterol content) were
discriminated. We were also able to discriminate between glioma
(clusters 4, 5), peri-necrosis and necrosis (clusters 7 and 8), full
necrosis (cluster 2), and edema (clusters 11 and 6) in the second
groups.
4. Discussion
Our results demonstrate the potential of Raman microspectro-
scopic imaging to successfully discriminate between healthy and
tumor tissue, and to characterize the invasive, necrotic, and
edematous regions. The C6 rat gliomamodel was chosen because
of its similar morphology to glioblastoma multiform, its rapid
proliferative rate, and its reproducibility, criteria often desired for
an in vivo experimental brain tumor [16–18]. Raman maps
allowed clear identification of the anatomical structures of the
healthy rat brain (CC and cortex), and visualization of the changes
associated with tumor and necrosis. Healthy cerebral parenchyma
was characterized by an important lipid content, whereas tumor
tissue was characterized by an important protein content. Pseudo-
color maps allowed a clear modeling of all cerebral structures
such as CC and cortex. The difference spectrum between CC and
adjacent tissue contained a combination of bands characteristic of
cholesterol, phosphatidylethanolamine and/or phosphatidylcho-
line and galactocerebroside, in agreement with the data of Krafft
et al. [12]. These lipids are essential components of myelin which
contains high molar percentages of cerebroside, cerebroside
sulphate, and cholesterol [19–21]. The proportions of cholesterol
and galactocerebroside decreased gradually from CC towards the
surface of the cortex. This gradient is related to myelin content as
found in various cortical layers [22] in a previous study using
luxol fast blue staining to visualize myelin distribution in brain
tissue and to map particular cortex sections [13].
Tumor development was characterized by a reduction in total
lipid content, including cholesterol. This result, in agreement with
those obtained in brain diseases [23], is correlated with demy-elination. This lowering in lipid content in malignant tissues
might be related to the fast growth of tumor cells which needmore
energy [24]. Indeed, it is known that in developing brain tumors,
structural and functional cell changes take place in which lipids
play a crucial role. Yet, qualitative and quantitative aspects of lipid
changes in brain tumors of different degrees of malignancy are
still the subject of numerous studies [25]. Using Infrared micro-
spectroscopy, Krafft et al. have evaluated the usefulness of the
lipid-to-protein ratio (2850/1655 cm−1) as a spectroscopic marker
to discriminate between normal and tumor tissue, as well as
between low- and high-grade glioma tissues. They demonstrated
that this ratio is maximal for normal brain tissue and decreases with
the progression of the disease [25]. In general, an increase in
malignancy is accompanied by a reduction in total lipids that
involves allmain classes of lipids found in plasmamembranes [26].
Changes in lipid and in phospholipids content, as seen in
glioblastoma as compared with adjacent tissue, could indicate an
evolution in the undergoing pathological process. Increased levels
of cholesterol esters (cholesterol oleate and linoleate) have also
been reported in glioma tissue [10]. Koljenoviv et al. demonstrated
that the difference between meningioma and dura is mainly related
to lipids, cholesterol linoleate and linoleic acid levels. Steiner et al.
studied the discriminating constituents between normal and
tumoral tissues (astrocytoma and glioblastoma) by infrared
spectroscopy. They demonstrated that changes mainly arise from
differences in lipid constituents. The potential use of lipid mea-
surements for judging the stage, and hence the prognosis, of low-
grade tumors is suggested by the apparent gradual increase in lipid
content over time. This increase, believed to be associated with
necrosis, could thus be used in low-grade tumors as an earlymarker
of disease prior to the patient becoming symptomatic [27–29].
Glioblastoma is the most malignant brain tumor as it aggres-
sively proliferates and invades surrounding normal brain
tissues. Ki-67 and MT1-MMP staining associated with the
proliferative and invasive activities of glioblastoma, respec-
tively, were clearly correlated with cluster 4 that encoded the
surrounding area. In fact, previous work showed that MT1-
MMP is expressed on the surface of rat C6 glioblastoma cells as
its metalloproteolytic activity is required to overcome myelin's
inhibitory effect on cell migration [30]. The lack of MT1-MMP
expression in normal brain (data not shown) indicates that MT1-
MMP expression is abnormally activated in neoplastic glial
cells, and thus suggests that overexpression of MT1-MMP
might facilitate tumor invasiveness through the activation of
MMP-2 [31]. The correlation between immunohistochemistry
staining results and spectroscopic data shows the potential of
Raman spectroscopy to provide spectroscopic markers associ-
ated with the proliferative and invasive properties of glioblas-
toma. This finding is very important for future developments of
in vivo Raman spectroscopy to accurately define tumor mar-
gins, to identify tumor remnants in glioma, and to help in the
development of novel therapies for glioblastoma [32].
A particular cluster (cluster 11) needs to be highlighted. This
cluster, which is located in tumor and in tissue adjacent to the
tumor (i.e. Caudate Putamen), displays characteristics of blood
spectra, and particularly of plasma. It is now well known that
brain tumors alter the permeability of the blood–brain barrier,
2613N. Amharref et al. / Biochimica et Biophysica Acta 1768 (2007) 2605–2615which leads to extravasation of a protein-rich plasma filtrate
into the interstitial space with subsequent accumulation of vas-
cular fluid [33]. Vasogenic edema, the most common type of
edema associated with brain tumors, is found in both grey and
white matter, and is located in extracellular spaces. Histological
study of H&E stained sections revealed an enlargement of the
extracellular fluid volume which provides an evidence of brain
edema [34]. The latter is one of the most important factors
leading to morbidity and mortality associated with brain tumors.
By definition, brain edema is characterized by an increase in
brain volume resulting from increased water, sodium and serum
protein content. In the difference spectrum between edema
(cluster 11) and tumor (cluster 5), several bandswere associated to
plasma proteins and could thus be used as spectroscopic markers
to identify the edema. Hydrostatic and osmotic forces encourage
the movement of fluid out of the vascular compartment into the
parenchyma resulting in amass effect. Brain compression leads to
abnormal diffusion of nutrients which results in acidosis, hypoxia,
and inflammatory changes. The edema fluid contains serum
proteins and various bioactive substances released by the tumor
[35] which can damage the tissue [36]. To our knowledge, this is
the first time that an identification of the tumoral and associated
tumoral edemawas carried out byRamanmicrospectroscopy. In a
preceeding article [13], we described a particular structure located
around the tumor that was associated with peritumoral edema.
Raman imaging thus confirmed these results previously obtained
by infrared spectroscopy.
The presence of necrosis is important for grading tumors, and
is often linked to a poorer clinical prognosis [37,38]. Therefore,
we attempted to identify the necrotic part of the glioma. In this
glioblastoma model, two different regions were identified: the
center of the necrotic zone and a peri-necrotic and necrotic zone.
Raman spectra revealed the presence of blood in the center of
necrotic zones and a high lipid content in the peri-necrotic zones.
As such, necrosis, induced by different stimuli including
hypoxia, is accompanied by ion and water efflux and dispersal
of organelles, coming from membrane cell rupture [39], and the
necrotic core is a result of hypoxia [40]. Themost necrotic part of
the tumor was characterized by the presence of plasma proteins
(due to edema) and of proteins from the cytoplasm of necrotic
cells. One pathological feature that distinguishes glioblastoma
from lower grade astrocytomas and which can explain the abrupt
change in biological behaviour is the presence of pseudopalisad-
ing necrosis, a dense collection of neoplastic cells surrounding a
central necrotic focus. In fact, the presence of pseudopalisading
necrosis and the increased levels of angiogenesis, markers of
glioblastoma, are pathophysiologically linked and mechanisti-
cally instrumental to disease progression [41–43]. Nile red
staining was used to identify the nature and the distribution of
lipids in these tissues. Our results demonstrate that cells sur-
rounding necrosis contain lipid droplets (neutral lipids). Non-lipid
droplets were also found in the central part of necrosis that could
be related to the extent of the necrotic zone. Previous studies using
magnetic resonance spectroscopy have reported the presence of
lipid droplets in C6 glioma and in human brain tumors [44–47],
and their presence has been attributed to the rapid tumoral growth
[48]. The central part of necrosis was mainly composed ofproteins, and Raman spectra reflected the presence of plasmatic
compounds. This result is in agreement with the extravasation of
plasma proteins as found in glioma [35].
There are only a few studies using vibrational spectroscopy for
the characterization of necrosis [49,28]. Koljenvic et al. have
discriminated vital from necrotic glioblastoma tissues by Raman
microspectroscopy. They demonstrated that necrotic tissue contains
higher levels of cholesterol than vital tumor tissue. Yamada et al.
came to the same conclusions by comparing necrotic and vital
carcinoma tissues [49]. Our tumor models were characterized by a
large necrotic area with complete necrosis in the center. The
necrotic zones were very heterogeneous and could be graded as
either complete or partial. Neutral lipids were absent from the
completely necrotic region (as confirmed by Nile red staining)
whereas theyweremore commonly found in the peri-necrotic zone.
Our study shows the ability of Raman spectroscopy to
accurately diagnose normal, tumoral, and necrotic tissue ex-vivo.
For ex-vivo measurements, Raman microspectroscopy, in which
high NA microscopic lenses are employed, allows measurements
with a high spatial resolution and good signal collection efficiency.
Recent developments in optic fiber probes now enable signal
collection times of about 1 s, a time short enough for medical
applications [50,51]. A recent study has demonstrated the potential
of Raman spectroscopy for real-time margin assessment during
partial mastectomy surgery by providing detailed quantitative
chemical information of tissue margins [51]. This modelling
approach is based on the assumptions that the Raman spectrum
measured on breast tissue is a linear combination of the spectra of
its individual tissue components. The comparison between tissue
composition extracted from normal and tumor through modelling
(the fit coefficient) was used to diagnose morphological and
structural changes associated with disease.
5. Conclusion
The combination of Raman microspectroscopy with multivar-
iate analysis has a clear potential in providing an objective
diagnostic complimentary to that obtained by histopathology, and
can lead to a better understanding of the molecular changes asso-
ciated with tumor. In this study, we successfully discriminated
between normal structures, tumoral, peri-tumoral, necrotic, and
edematous zones in brain tissue. Structural changes were mainly
related to qualitative and quantitative changes in lipid content that
can be used as spectroscopic markers for this pathology. Addi-
tionally, a particular cluster was found and attributed to edema in
agreement with the histopathologist's opinion. By combining
spectral results with Ki-67 andMT1-MMP immunohistochemical
staining, the proliferative and invasive activities of glioblastoma
can be detected in the periphery of the tumor tissue. Two different
regions were identified in the necrotic part of the glioma: a center
mainly associated to plasma proteins, and a peri-necrotic zone
containing a high proportion of lipid droplets.
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